Non-alcoholic Fatty Liver Disease Clinical Trial
Official title:
Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver
Verified date | June 2021 |
Source | Kanazawa University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The clinicopathological analyses revealed that reduction in HbA1c and use of insulin independently contribute to the reduction in liver fibrosis scores during the histological course of NAFLD development. These findings led us to hypothesize that glycemic control and insulin ameliorate or protect against the histological progression of liver fibrosis in patients with NAFLD. In the present study, we investigated the efficacy of SGLT2 inhibitor tofogliflozin and sulfonylurea glimepiride, which lower glucose levels similarly with reduction and elevation in circulating insulin levels, respectively, in NAFLD patients with type 2 diabetes for 48 weeks by examining liver histology, as well as hepatic enzymes, metabolic markers, and hepatic gene expression profiles.
Status | Completed |
Enrollment | 40 |
Est. completion date | June 30, 2021 |
Est. primary completion date | December 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | The trial entry criteria are based on: 1. A diagnosis of "definite" NAFLD on liver biopsy obtained within 3 months of screening. 2. =20 years of age at the time of the initial screening. 3. Patients with type 2 diabetes mellitus at the time of screening need to have glycemic control (HbA1c of =7%) and have been managed by either diet and/or a stable dose of hypoglycemic agents for at least 4 weeks. Exclusion Criteria 1. Hepatic virus infections (hepatitis B and C, cytomegalovirus, and Epstein-Barr virus), autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, hemochromatosis, alpha 1-antitrypsin deficiency, Wilson's disease, history of parenteral nutrition. 2. Use of agents known to induce steatosis (e.g., valproate, amiodarone, or vitamin E) 3. Hepatic injury caused by substance abuse. 4. Current consumption of more than 20 g of alcohol daily. 5. Hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding 6. Elevated serum bilirubin level of more than two-fold the upper normal limit. 7. Tofogliflozin or glimepiride hypersensitivity or contraindications. 8. History of type 1 diabetes. 9. History of ketoacidosis. 10. History of symptoms of severe hypoglycemia. 11. Treatment with SGLT2 inhibitor including tofogliflozin within 4 weeks of screening. 12. Treatment with glinide and sulfonylurea use within 4 weeks of screening. 13. Concomitant corticosteroid therapy uses within 4 weeks of screening. 14. Poorly controlled unstable diabetes (ketoacidosis or an increase in HbA1c of >3% in the 12 weeks before screening). 15. Poorly controlled hypertension or systolic blood pressure of >160 mmHg or diastolic blood pressure of >100 mmHg. 16. Artificial dialysis or moderate renal dysfunction. 17. Poorly controlled dyslipidemia. 18. Presence of a severe health problem, not being suitable for the study. 19. Pregnant or breastfeeding. 20. Inability to participate in the study (including psychiatric and psychosocial problems), as assessed by the investigators. |
Country | Name | City | State |
---|---|---|---|
Japan | Kanazawa University Graduate School of Medical Sciences | Kanazawa | Ishikawa |
Lead Sponsor | Collaborator |
---|---|
Kanazawa University | Kowa Company, Ltd. |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The improvement in histologic features of NAFLD | 48 weeks | ||
Secondary | Change from baseline in liver enzymes | 48 weeks | ||
Secondary | Change from baseline in body composition | 48 weeks | ||
Secondary | Change from baseline in fasting plasma glucose level and glucose metabolism assessed with arginine tolerance test | 48 weeks | ||
Secondary | Changes from baseline in organ-specific insulin sensitivity and glucagon response during a euglycemic hyperinsulinemic clamp study | 48 weeks | ||
Secondary | Change from baseline in lipid profile | 48 weeks | ||
Secondary | Change from baseline in renal function and electrolyte balances | 48 weeks | ||
Secondary | Change from baseline in oxidative stress | 48 weeks | ||
Secondary | Change from baseline in cytokine (TNF-alpha, leptin, adiponectin) levels | 48 weeks | ||
Secondary | Change from baseline in hepatokine (Selenoprotein P, LECT2) levels | 48 weeks | ||
Secondary | Change from baseline in organ-specific fat accumulation | 48 weeks | ||
Secondary | Change from baseline in oxidative and non-oxidative glucose disposal | 48 weeks | ||
Secondary | Change from baseline in respiratory quotients | 48 weeks | ||
Secondary | Change from baseline in energy expenditure | 48 weeks | ||
Secondary | Change from baseline in autonomic nerve function. | 48 weeks | ||
Secondary | Changes from baseline in minerals and bone metabolism | 48 weeks | ||
Secondary | Changes from baseline in endothelial functions | 48 weeks | ||
Secondary | Changes from baseline in fatty acids profiles | 48 weeks | ||
Secondary | Factors associated with the changes in autonomic nerve function, organ-specific fat accumulation, and glucagon response. | 48 weeks | ||
Secondary | Changes from baseline in gene expression profiles in the liver and blood cells | 48 weeks | ||
Secondary | Changes from baseline in microRNAs and exosome contents | 48 weeks | ||
Secondary | Epigenomic changes from baseline in genes of the liver and blood cells | 48 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |